Related references
Note: Only part of the references are listed.Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment
Gregory S. Calip et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2015)
The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer
Susan A. Sabatino et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer
Denise M. Boudreau et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients
S. Jiralerspong et al.
ANNALS OF ONCOLOGY (2013)
Frequent Antibiotic Use and Second Breast Cancer Events
Heidi S. Wirtz et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
Association Between Metformin Therapy and Mortality After Breast Cancer A population-based study
Iliana C. Lega et al.
DIABETES CARE (2013)
Threats to Validity of Nonrandomized Studies of Postdiagnosis Exposures on Cancer Recurrence and Survival
Jessica Chubak et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Use of Metformin and Survival of Diabetic Women with Breast Cancer
Paul J. H. L. Peeters et al.
CURRENT DRUG SAFETY (2013)
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+breast cancer
X. He et al.
ANNALS OF ONCOLOGY (2012)
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
Soley Bayraktar et al.
CANCER (2012)
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study
R. Ruiter et al.
DIABETOLOGIA (2012)
Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database
P. Blin et al.
DIABETOLOGIA (2012)
Diabetes, Metformin, and Breast Cancer in Postmenopausal Women
Rowan T. Chlebowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
Bernardo Bonanni et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes
Marcus Lind et al.
PRIMARY CARE DIABETES (2012)
Relationship between diabetes and risk of second primary contralateral breast cancer
Christopher I. Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer A retrospective cohort study of older Medicare patients
Nancy E. Morden et al.
DIABETES CARE (2011)
Long-term effects of insulin glargine on the risk of breast cancer
S. Suissa et al.
DIABETOLOGIA (2011)
Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care
Andrea DeCensi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis
Kimberly S. Peairs et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients - A Nationwide Cohort Study
Chia-Hsuin Chang et al.
PLOS ONE (2011)
Multimorbidity: An Issue of Growing Importance for Oncologists
Christine S. Ritchie et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Metformin: A Therapeutic Opportunity in Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2010)
Diabetes and Cancer A consensus report
Edward Giovannucci et al.
DIABETES CARE (2010)
Evaluating Health Outcomes in the Presence of Competing Risks A Review of Statistical Methods and Clinical Applications
Ravi Varadhan et al.
MEDICAL CARE (2010)
In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
Mark R. Sommerfeld et al.
PLOS ONE (2010)
Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells
Doris Mayer et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2010)
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. J. Currie et al.
DIABETOLOGIA (2009)
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Sao Jiralerspong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A population-based osteoporosis screening program: Who does not participate, and what are the consequences?
DSM Buist et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2004)
Impact of healthcare delivery system on where HMO-enrolled seniors purchase medication
DM Boudreau et al.
ANNALS OF PHARMACOTHERAPY (2004)
Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes
KM Newton et al.
DIABETES CARE (2003)
Staging system for breast cancer:: revisions for the 6th edition of the AJCC Cancer Staging Manual
SE Singletary et al.
SURGICAL CLINICS OF NORTH AMERICA (2003)
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
P Kurtzhals et al.
DIABETES (2000)
Share Paper
